252 related articles for article (PubMed ID: 21557276)
1. Finasteride upregulates expression of androgen receptor in hyperplastic prostate and LNCaP cells: implications for chemoprevention of prostate cancer.
Hsieh JT; Chen SC; Yu HJ; Chang HC
Prostate; 2011 Jul; 71(10):1115-21. PubMed ID: 21557276
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of MENT on primary cell cultures from benign prostatic hyperplasia and prostate carcinoma.
Mendoza P; Sánchez C; Contreras HR; Vergara J; Acevedo C; Cabezas J; Huidobro C; Noé G; Castellón EA
Int J Androl; 2009 Dec; 32(6):607-15. PubMed ID: 18637152
[TBL] [Abstract][Full Text] [Related]
3. Comment on "Finasteride upregulates expression of androgen receptor in hyperplastic prostate and LNCaP cells: implications for chemoprevention of prostate cancer" by Hsieh et al.
Friedman AE
Prostate; 2012 May; 72(7):703-4. PubMed ID: 21882213
[No Abstract] [Full Text] [Related]
4. Five-alpha reductase inhibitor influences expression of androgen receptor and HOXB13 in human hyperplastic prostate tissue.
Jung C; Park Y; Kim YR; Ryu SB; Kang TW
Int Braz J Urol; 2013; 39(6):875-83. PubMed ID: 24456780
[TBL] [Abstract][Full Text] [Related]
5. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
[TBL] [Abstract][Full Text] [Related]
6. Effects of competitive and noncompetitive 5α-reductase inhibitors on serum and intra-prostatic androgens in beagle dogs.
Zhao XF; Yang Y; Wang W; Qiu Z; Zhang P; Wang B
Chin Med J (Engl); 2013 Feb; 126(4):711-5. PubMed ID: 23422194
[TBL] [Abstract][Full Text] [Related]
7. Finasteride treatment alters tissue specific androgen receptor expression in prostate tissues.
Bauman TM; Sehgal PD; Johnson KA; Pier T; Bruskewitz RC; Ricke WA; Huang W
Prostate; 2014 Jun; 74(9):923-32. PubMed ID: 24789081
[TBL] [Abstract][Full Text] [Related]
8. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
Habib FK; Ross M; Tate R; Chisholm GD
Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
[TBL] [Abstract][Full Text] [Related]
9. Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer.
Suzuki K; Nishiyama T; Hara N; Yamana K; Takahashi K; Labrie F
Prostate Cancer Prostatic Dis; 2007; 10(3):301-6. PubMed ID: 17387321
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors.
Wu Y; Godoy A; Azzouni F; Wilton JH; Ip C; Mohler JL
Prostate; 2013 Sep; 73(13):1470-82. PubMed ID: 23813697
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer.
Das K; Lorena PD; Ng LK; Lim D; Shen L; Siow WY; Teh M; Reichardt JK; Salto-Tellez M
Endocr Relat Cancer; 2010 Sep; 17(3):757-70. PubMed ID: 20519274
[TBL] [Abstract][Full Text] [Related]
13. New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line.
Amaral C; Varela C; Correia-da-Silva G; Tavares da Silva E; Carvalho RA; Costa SC; Cunha SC; Fernandes JO; Teixeira N; Roleira FM
Biochimie; 2013 Nov; 95(11):2097-106. PubMed ID: 23933094
[TBL] [Abstract][Full Text] [Related]
14. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
Arnold JT; Le H; McFann KK; Blackman MR
Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor gene alterations and chromosomal gains and losses in prostate carcinomas appearing during finasteride treatment for benign prostatic hyperplasia.
Koivisto PA; Schleutker J; Helin H; Ehren-van Eekelen C; Kallioniemi OP; Trapman J
Clin Cancer Res; 1999 Nov; 5(11):3578-82. PubMed ID: 10589774
[TBL] [Abstract][Full Text] [Related]
16. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.
Geller J
J Clin Endocrinol Metab; 1990 Dec; 71(6):1552-5. PubMed ID: 1699965
[TBL] [Abstract][Full Text] [Related]
17. Androgen sensitivity of prostate epithelium is enhanced by postnatal androgen receptor inactivation.
Simanainen U; McNamara K; Gao YR; Handelsman DJ
Am J Physiol Endocrinol Metab; 2009 Jun; 296(6):E1335-43. PubMed ID: 19366880
[TBL] [Abstract][Full Text] [Related]
18. [Hormonal therapy for benign prostatic hyperplasia].
Sakai H; Kanetake H
Nihon Rinsho; 2002 Dec; 60 Suppl 11():358-61. PubMed ID: 12599600
[No Abstract] [Full Text] [Related]
19. The direct inhibitory effect of dutasteride or finasteride on androgen receptor activity is cell line specific.
Chhipa RR; Halim D; Cheng J; Zhang HY; Mohler JL; Ip C; Wu Y
Prostate; 2013 Oct; 73(14):1483-94. PubMed ID: 23813737
[TBL] [Abstract][Full Text] [Related]
20. 5 alpha-reductase activity in cultured epithelial and stromal cells from normal and hyperplastic human prostates--effect of finasteride (Proscar), a 5 alpha-reductase inhibitor.
Boudon C; Lobaccaro JM; Lumbroso S; Lechevallier E; Mottet N; Gibelin B; Sultan C
Cell Mol Biol (Noisy-le-grand); 1995 Dec; 41(8):1007-15. PubMed ID: 8747081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
